Angiodynamics

To improve patient care with innovative tech by becoming the leader in minimally-invasive therapies for vascular and oncology.

Angiodynamics SWOT Analysis

Updated: October 4, 2025 • 2025-Q4 Analysis

How to Use This Analysis

This analysis for Angiodynamics was created using Alignment.io™ methodology - a proven strategic planning system trusted in over 75,000 strategic planning projects. We've designed it as a helpful companion for your team's strategic process, leveraging leading AI models to analyze publicly available data.

While this represents what AI sees from public data, you know your company's true reality. That's why we recommend using Alignment.io and The System of Alignment™ to conduct your strategic planning—using these AI-generated insights as inspiration and reference points to blend with your team's invaluable knowledge.

Powered by Leading AI Models

Anthropic

Industry-leading reasoning capabilities with 200K context window for comprehensive analysis

Google Gemini

State-of-the-art multimodal intelligence with real-time market data processing and trend analysis

OpenAI GPT

Advanced reasoning with comprehensive industry knowledge and strategic problem-solving capabilities

The AngioDynamics SWOT analysis reveals a company at a critical inflection point. Its strategic pivot to high-growth Med Tech platforms like Auryon and NanoKnife is yielding impressive top-line results, representing a formidable strength. However, this is contrasted by the drag from its legacy Med Device segment and persistent unprofitability. The primary opportunity lies in securing new, high-value indications, particularly for NanoKnife in prostate cancer, which could be transformative. The greatest threat is intense competition from deeply-resourced players who could blunt AngioDynamics' momentum. The path forward requires relentless focus on commercial execution for its star products, successful clinical trial completion, operational discipline to drive profitability, and strategic international expansion. Success hinges on converting innovative technology into sustainable market leadership and financial performance.

Boston Scientific Medtronic Abbott Laboratories Penumbra Inari Medical

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To improve patient care with innovative tech by becoming the leader in minimally-invasive therapies for vascular and oncology.

Toggle Theme

Strengths

GROWTH: Med Tech revenue up 37.3% YoY, led by Auryon (+53%) in Q3'24.
INNOVATION: NanoKnife shows strong promise with 41% YoY growth, new trials.
FOCUS: Clear strategic pivot to high-margin, high-growth platforms works.
DATA: Growing body of clinical evidence supports technology adoption.
LEADERSHIP: Experienced management team successfully executing turnaround.

Weaknesses

LEGACY: Flat/declining Med Device segment (-0.5%) drags on total growth.
PROFITABILITY: Continued net losses (-$9.9M in Q3'24) amid investments.
SCALE: Operational inefficiencies limit gross margin expansion potential.
DEPENDENCE: Heavy reliance on just two platforms for future company growth.
CASH: Limited cash reserves may constrain future R&D or M&A activities.

Opportunities

PROSTATE: DIRECT trial for NanoKnife could unlock a multi-billion $ market.
INTERNATIONAL: OUS expansion represents a significant untapped revenue stream.
THROMBECTOMY: AlphaVac launch can capture share in a high-growth market.
PARTNERSHIPS: Collaborate with AI firms to enhance treatment planning tools.
AWARENESS: Increased physician and patient education on PAD and treatment.

Threats

COMPETITION: Intense rivalry from larger players like Boston Sci, Medtronic.
REIMBURSEMENT: Payer pushback or coding changes could impact procedure volume.
EXECUTION: Faltering on clinical trial execution could delay key approvals.
SUPPLY CHAIN: Continued disruptions for key components impacting production.
MACROECONOMIC: Hospital capital budget constraints slowing device adoption.

Key Priorities

COMMERCIALIZE: Maximize Auryon & NanoKnife growth via sales force expansion.
INNOVATE: Secure prostate cancer indication for NanoKnife via DIRECT trial.
OPTIMIZE: Improve gross margins by streamlining Med Device manufacturing.
EXPAND: Build foundational infrastructure for targeted international growth.

Create professional SWOT analyses in minutes with our AI template. Get insights that drive real results.

Get Free SWOT Analysis Template

Angiodynamics OKR

Updated: October 4, 2025 • 2025-Q4 Analysis

The AngioDynamics OKR plan is a masterclass in strategic alignment. It directly translates the SWOT's core conclusions into four potent, inspiring objectives: driving growth, winning in oncology, achieving profitability, and expanding globally. The key results are sharp, outcome-focused, and directly address the company's most critical levers for success—from Auryon sales velocity and DIRECT trial execution to gross margin improvement. This plan provides extreme clarity, creating a direct line of sight between daily actions and the long-term vision. It effectively focuses the entire organization on the vital few priorities required to transform AngioDynamics into a profitable, high-growth leader in medical technology, embodying a relentless focus on what truly matters.

Boston Scientific Medtronic Abbott Laboratories Penumbra Inari Medical

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To improve patient care with innovative tech by becoming the leader in minimally-invasive therapies for vascular and oncology.

DRIVE PLATFORM GROWTH

Dominate our core markets with Auryon and NanoKnife.

AURYON: Increase Auryon disposable revenue by 45% by expanding into 100 new hospital accounts.
NANOKNIFE: Grow NanoKnife probe revenue by 40% through targeted commercial focus on top 50 cancer centers.
ALPHAVAC: Achieve $15M in AlphaVac revenue by successfully launching the F22 system and training 200 physicians.
SALES: Expand the Med Tech sales team by 25% with reps fully trained and certified on all platforms.

WIN IN ONCOLOGY

Establish NanoKnife as the standard of care for prostate.

TRIAL: Complete enrollment for the pivotal DIRECT trial for prostate cancer indication ahead of schedule.
DATA: Present positive interim data from the DIRECT trial at a major urological medical conference.
SUBMISSION: Prepare and finalize the PMA submission package for the FDA, ready for submission upon trial completion.
KOL: Establish a medical advisory board with 10 leading urologic oncologists to guide market strategy.

ACHIEVE PROFITABILITY

Build a sustainable financial model for long-term growth.

MARGIN: Increase consolidated gross margin by 300 basis points through improved product mix and efficiencies.
OPERATIONS: Reduce Med Device unit manufacturing costs by 10% via a targeted lean process initiative.
SPEND: Maintain SG&A and R&D spending within 1% of the approved annual operating plan budget.
INVENTORY: Decrease inventory days on hand by 15% to improve cash conversion cycle and free up capital.

EXPAND GLOBALLY

Establish a beachhead for growth in key global markets.

EUROPE: Secure regulatory approval and achieve first commercial sale of Auryon in two key EU countries.
APAC: Sign distribution agreements for NanoKnife in Japan and Australia with partners having proven track records.
INFRASTRUCTURE: Develop and approve a 3-year international registration and commercialization roadmap.
REVENUE: Achieve $10M in revenue from markets outside of the United States for the Med Tech portfolio.

METRICS

Med Tech Platform Revenue Growth: 35%+
Consolidated Gross Margin: 58%+
Adjusted EBITDA: Positive

VALUES

Patient-First
Integrity
Innovation
Performance-Driven
Teamwork

Build strategic OKRs that actually work. AI insights meet beautiful design for maximum impact.

Get Free OKR Template

Angiodynamics Retrospective

AI-Powered Insights

Claude

Gemini

GPT

AngioDynamics Q3 FY2024 Earnings Report and Press Release (March 2024)
AngioDynamics Investor Relations Website (Investor Presentations, SEC Filings)
Public financial data from Yahoo Finance for ANGO
Company website (angiodynamics.com) for mission, products, and leadership

Boston Scientific Medtronic Abbott Laboratories Penumbra Inari Medical

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To improve patient care with innovative tech by becoming the leader in minimally-invasive therapies for vascular and oncology.

Toggle Theme

What Went Well

AURYON: Maintained exceptional growth trajectory, exceeding market expectations.
NANOKNIFE: Strong sales growth validates continued investment and focus.
REVENUE: Overall revenue growth of 10.3% demonstrates successful strategy.
GUIDANCE: Company reaffirmed its full-year revenue guidance, showing confidence.
CLINICAL: Progress in the DIRECT trial for prostate cancer remains on track.

Not So Well

MARGINS: Gross margins remain below long-term targets due to product mix.
MED DEVICE: Legacy business continues to be a drag on overall performance.
PROFITABILITY: Operating losses persist due to high SG&A and R&D spend.
CASH FLOW: Negative cash flow from operations requires careful management.
SUPPLY: Mention of supply chain constraints impacting some product availability.

Learnings

FOCUS: Doubling down on Med Tech platforms is the correct and only path.
INVESTMENT: Sustained investment in sales and R&D is necessary for growth.
EFFICIENCY: Operational leverage has not yet been achieved and needs focus.
MARKET: The market rewards high-tech growth even with current unprofitability.
CLINICAL DATA: Positive clinical trial results are paramount for adoption.

Action Items

SALES: Continue hiring specialized sales reps for Auryon and NanoKnife.
OPERATIONS: Initiate a cost-optimization project for the Med Device unit.
R&D: Ensure the DIRECT clinical trial remains fully resourced and on schedule.
FINANCE: Maintain disciplined expense management to preserve cash runway.
MARKETING: Increase publication of clinical data to drive physician awareness.

Run better retrospectives in minutes. Get insights that improve your team.

Get Free Retro Template

Organization	SWOT Analysis	OKR Plan	Top 6	Retrospective

Explore specialized team insights and strategies

Angiodynamics Market

AI-Powered Insights

Claude

Gemini

GPT

AngioDynamics Q3 FY2024 Earnings Report and Press Release (March 2024)
AngioDynamics Investor Relations Website (Investor Presentations, SEC Filings)
Public financial data from Yahoo Finance for ANGO
Company website (angiodynamics.com) for mission, products, and leadership

Founded: 1988
Market Share: Niche player; growing share in atherectomy/thrombectomy.
Customer Base: Hospitals, interventional radiologists, vascular surgeons.
Category:
Medical Devices
SIC Code: 3841 Surgical and Medical Instruments and Apparatus
NAICS Code: 339112 Surgical and Medical Instrument Manufacturing
Location: Latham, New York
Zip Code: 12110
Congressional District: NY-20 ALBANY
Employees: 1200

Competitors

Boston Scientific View Analysis

Medtronic View Analysis

Abbott Laboratories View Analysis

Penumbra View Analysis

Inari Medical Request Analysis

Products & Services

No products or services data available

Distribution Channels

Angiodynamics Business Model Analysis

AI-Powered Insights

Claude

Gemini

GPT

AngioDynamics Q3 FY2024 Earnings Report and Press Release (March 2024)
AngioDynamics Investor Relations Website (Investor Presentations, SEC Filings)
Public financial data from Yahoo Finance for ANGO
Company website (angiodynamics.com) for mission, products, and leadership

Problem

High amputation rates from PAD
Limited options for soft-tissue tumors
Invasive, high-complication surgeries

Solution

Auryon: minimally invasive atherectomy
NanoKnife: targeted tumor ablation tech
Thrombectomy: mechanical clot removal

Key Metrics

Med Tech revenue growth rate
New physician adoption rates
Gross Margin Percentage

Unique

Proprietary 355nm laser in Auryon
Non-thermal IRE mechanism of NanoKnife
Growing body of supportive clinical data

Advantage

Strong patent portfolio (IP moat)
Installed base of capital equipment
Deep relationships with key opinion leaders

Channels

Direct sales force in major markets
International distributor network
Medical education and conferences

Customer Segments

Interventional Radiologists & Cardiologists
Vascular and Surgical Oncologists
Hospital administrators (value analysis)

Costs

R&D for new tech and clinical trials
Specialized direct sales force (SG&A)
Manufacturing and supply chain costs

Angiodynamics Product Market Fit Analysis

Updated: October 4, 2025

AngioDynamics provides physicians with breakthrough medical technologies to treat complex vascular disease and cancer. Its platforms deliver superior patient outcomes, reduce system-wide costs by enabling faster recovery, and offer new hope by treating conditions once considered untreatable. This transforms patient care through indispensable, minimally invasive innovation, creating significant value for both patients and providers.

DELIVERING superior patient outcomes with our innovative minimally invasive technologies.

ENABLING physicians to treat complex diseases that were previously untreatable.

REDUCING total healthcare costs through faster recovery and fewer complications.

Before State

Invasive surgeries for tumors & PAD
Limited treatment options for complex cases
High rates of complication and amputation

After State

Minimally invasive, targeted treatments
New options for previously untreatable tumors
Improved patient outcomes, limb salvage

Negative Impacts

Long patient recovery times, high costs
Poor quality of life for patients
Repeat, often ineffective, procedures

Positive Outcomes

Faster recovery, lower healthcare costs
Better patient survival and quality of life
Reduced need for follow-up interventions

Key Metrics

Auryon Revenue Growth Rate

53% YoY (Q3'24)

NanoKnife Revenue Growth Rate

41% YoY (Q3'24)

Customer Retention Rates

High due to disposable model

Net Promoter Score (NPS)

Not publicly available

User Growth Rate

Strong physician adoption for new tech

Customer Feedback/Reviews

Positive clinical study outcomes

Repeat Purchase Rates

High for disposable components

Requirements

Robust clinical evidence and data
Physician training and education programs
Securing broad reimbursement coverage

Why Angiodynamics

Pivotal trials like DIRECT for prostate
Expand direct sales force expertise
Targeted marketing at medical conferences

Angiodynamics Competitive Advantage

NanoKnife's non-thermal cell ablation
Auryon's unique 355nm laser wavelength
Strong IP protecting core technologies

Proof Points

Auryon's 53% YoY revenue growth (Q3'24)
NanoKnife's 41% YoY revenue growth (Q3'24)
Positive interim data from DIRECT trial

Angiodynamics Market Positioning

AI-Powered Insights

Claude

Gemini

GPT

AngioDynamics Q3 FY2024 Earnings Report and Press Release (March 2024)
AngioDynamics Investor Relations Website (Investor Presentations, SEC Filings)
Public financial data from Yahoo Finance for ANGO
Company website (angiodynamics.com) for mission, products, and leadership

Strategic pillars derived from our vision-focused SWOT analysis

Capture #1 U.S. atherectomy market share.

Drive adoption as standard of care in oncology.

Launch one breakthrough device annually.

Achieve top-quartile gross margins.

What You Do

Develops innovative, minimally invasive medical devices.

Target Market

Clinicians treating vascular disease and cancer.

Differentiation

Proprietary NanoKnife IRE technology
Auryon's 355nm laser for PAD treatment

Revenue Streams

Capital equipment sales (razor)
Disposable device sales (razor blade)

Angiodynamics Operations and Technology

AI-Powered Insights

Claude

Gemini

GPT

AngioDynamics Q3 FY2024 Earnings Report and Press Release (March 2024)
AngioDynamics Investor Relations Website (Investor Presentations, SEC Filings)
Public financial data from Yahoo Finance for ANGO
Company website (angiodynamics.com) for mission, products, and leadership

Company Operations

Organizational Structure: Functional structure with business unit focus.
Supply Chain: Global network of suppliers for complex components.
Tech Patents: Extensive patent portfolio for core technologies.
Website: https://www.angiodynamics.com/

Top Clients

Board Members

Angiodynamics Competitive Forces

Threat of New Entry

Low: High barriers to entry due to extensive R&D costs, complex regulatory hurdles (FDA approval), and the need for established sales channels.

Supplier Power

Moderate: Specialized components and contract manufacturing can create dependencies, but ANGO can multi-source for some parts, mitigating risk.

Buyer Power

High: Hospital systems and GPOs consolidate purchasing power, exerting significant pricing pressure and demanding strong clinical/economic data.

Threat of Substitution

Moderate: While surgical alternatives exist, the trend is toward minimally invasive tech. New modalities from competitors are the primary risk.

Competitive Rivalry

High: Dominated by large, well-funded players like Medtronic, Boston Scientific, and Abbott who have extensive portfolios and sales channels.

Analysis of AI Strategy

Updated: October 4, 2025 • 2025-Q4 Analysis

The AngioDynamics AI SWOT analysis highlights a significant opportunity gap. The company's core strength is its unique, proprietary data generated from its innovative platforms, which is the essential fuel for any AI initiative. However, this is severely undermined by a lack of internal AI talent, infrastructure, and a hardware-centric culture. The most compelling opportunity is to develop AI-powered treatment planning software for NanoKnife, which would create a powerful competitive moat and improve patient outcomes. The primary threat is that well-capitalized competitors will out-innovate them by integrating AI more effectively, diminishing AngioDynamics' current technological edge. The strategic imperative is clear: AngioDynamics must aggressively partner or acquire AI capabilities and build a data-centric culture, starting with a key leadership hire, to secure its long-term vision.

Boston Scientific Medtronic Abbott Laboratories Penumbra Inari Medical

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To improve patient care with innovative tech by becoming the leader in minimally-invasive therapies for vascular and oncology.

Strengths

DATA: Access to proprietary clinical and device performance data sets.
PLATFORMS: Existing tech (NanoKnife) is ideal for AI-guided therapy.
CLINICAL: Deep expertise in trial design can validate AI algorithms.
FOCUS: Niche market focus allows for specialized AI model development.

Weaknesses

TALENT: Lack of in-house AI/ML engineering and data science expertise.
INFRASTRUCTURE: No established data architecture for large-scale AI/ML.
INVESTMENT: Limited capital to compete with tech giants on AI R&D spend.
CULTURE: Historically a hardware-focused company, not a software/AI one.

Opportunities

PLANNING: Develop AI tools for pre-operative treatment planning with NanoKnife.
OUTCOMES: AI models to predict patient outcomes and personalize therapy.
EFFICIENCY: Use AI to optimize supply chain and manufacturing processes.
TRIALS: Leverage AI to accelerate clinical trial recruitment and analysis.

Threats

COMPETITORS: Large rivals integrate superior AI, making ANGO tech obsolete.
REGULATION: FDA/global bodies create high barriers for AI in medical devices.
DATA PRIVACY: Breaches of patient data could lead to severe legal penalties.
ADOPTION: Physician resistance to adopting AI-driven recommendations in care.

Key Priorities

PARTNER: Acquire or partner with a specialized medical imaging AI company.
PLANNING: Build an AI-powered treatment planning module for NanoKnife.
DATA: Create a unified data infrastructure to support ML model training.
TALENT: Hire a Chief AI Officer to build a team and drive the strategy.

Create professional SWOT analyses in minutes with our AI template. Get insights that drive real results.

Get Free SWOT Analysis Template

Angiodynamics Financial Performance

AI-Powered Insights

Claude

Gemini

GPT

AngioDynamics Q3 FY2024 Earnings Report and Press Release (March 2024)
AngioDynamics Investor Relations Website (Investor Presentations, SEC Filings)
Public financial data from Yahoo Finance for ANGO
Company website (angiodynamics.com) for mission, products, and leadership

Profit: Net Loss: -$38.9 million (TTM)

Market Cap: $350 million (approx. June 2024)

Stock Performance

Annual Report: Available on company's investor relations website.

Debt: Total Debt: $45.0 million (as of Feb 2024)

ROI Impact: Profitability challenged by R&D and SG&A investment.

SWOT Index

Composite strategic assessment with 10-year outlook

/ 100

Category Challenger

ICM Index

STRATEGIC ADVISOR ASSESSMENT

AngioDynamics has a strong, societally-impactful vision (Ambition: 85) with a credible strategy, though execution risk remains (Achievability: 0.70). The OKRs are category-shaping but not yet world-shaping. Its significant upside from novel tech is balanced by intense competitive threats, resulting in a moderate SWOT score. The company is a focused challenger with potential to become a market leader if it successfully executes its clinical and commercial strategy, particularly with NanoKnife's new indications.

SWOT Factors

Upside: 83.3 Risk: 76.7

OKR Impact

AI Leverage

Top 3 Strategic Levers

EXECUTE DIRECT trial flawlessly to unlock prostate market.

DRIVE Auryon adoption to fund future innovation.

ACQUIRE or partner to accelerate AI/software capabilities.

AI Disclosure

This report was created using the Alignment Method—our proprietary process for guiding AI to reveal how it interprets your business and industry. These insights are for informational purposes only and do not constitute financial, legal, tax, or investment advice.

Next Step

Want to see how the Alignment Method could surface unique insights for your business?

Request your custom report Contact our team

About Alignment LLC

Alignment LLC specializes in AI-powered business analysis. Through the Alignment Method, we combine advanced prompting, structured frameworks, and expert oversight to deliver actionable insights that help companies understand how AI sees their data and market position.